Literature DB >> 29909598

Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Pedro Iglesias1, Víctor Rodríguez Berrocal2, Juan José Díez3.   

Abstract

Giant pituitary adenomas comprise about 6-10% of all pituitary tumors. They are mostly clinically non-functioning adenomas and occur predominantly in males. The presenting symptoms are usually secondary to compression of neighboring structures, but also due to partial or total hypopituitarism. Functioning adenomas give rise to specific symptoms of hormonal hypersecretion. The use of dopamine agonists is considered a first-line treatment in patients with giant macroprolactinomas. Somatostatin analogs can also be used as primary treatment in cases of growth hormone and thyrotropin producing giant adenomas, although remission of the disease is not achieved in the vast majority of these patients. Neurosurgical treatment, either through transsphenoidal or transcranial surgery, continues to be the treatment of choice in the majority of patients with giant pituitary adenomas. The intrinsic complexity of these tumors requires the use of different therapies in a combined or sequential way. A multimodal approach and a therapeutic strategy involving a multidisciplinary team of expert professionals form the basis of the therapeutic success in these patients.

Entities:  

Keywords:  Acromegaly; Clinically non-functioning pituitary adenoma; Giant pituitary adenoma; Medical therapy; Neurosurgery; Prolactinoma; Radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29909598     DOI: 10.1007/s12020-018-1645-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  134 in total

1.  Incidence of pituitary adenomas in Northern Finland in 1992-2007.

Authors:  Antti Raappana; John Koivukangas; Tapani Ebeling; Tapio Pirilä
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients.

Authors:  Jackson A Gondim; Joao Paulo C Almeida; Lucas Alverne F Albuquerque; Michele Schops; Erika Gomes; Tania Ferraz; Wladia Sobreira; Meissa T Kretzmann
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

3.  Simultaneous transsphenoidal and transventricular endoscopic approaches for giant pituitary adenoma with hydrocephalus.

Authors:  Ender Koktekir; Hakan Karabagli; Kayhan Ozturk
Journal:  J Craniofac Surg       Date:  2015-01       Impact factor: 1.046

Review 4.  Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas.

Authors:  Ricardo J Komotar; Robert M Starke; Daniel M S Raper; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 5.  AIP mutations and gigantism.

Authors:  Liliya Rostomyan; Iulia Potorac; Pablo Beckers; Adrian F Daly; Albert Beckers
Journal:  Ann Endocrinol (Paris)       Date:  2017-05-05       Impact factor: 2.478

6.  [Rare observation of giant pituitary adenoma spreading into posterior cranial fossa].

Authors:  O F Tropinskaia; L V Shishkina; A N Shkarubo; L I Astaf'eva; V N Shimanskiĭ
Journal:  Zh Vopr Neirokhir Im N N Burdenko       Date:  2009 Oct-Dec

7.  A decade of pituitary microsurgery. The Herbert Olivecrona lecture.

Authors:  C B Wilson
Journal:  J Neurosurg       Date:  1984-11       Impact factor: 5.115

Review 8.  Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment.

Authors:  N Sanno; A Teramoto; R Y Osamura
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

9.  Reversible dementia due to macroprolactinoma. Case report.

Authors:  M H Brisman; M R Fetell; K D Post
Journal:  J Neurosurg       Date:  1993-07       Impact factor: 5.115

Review 10.  Histopathological classification of non-functioning pituitary neuroendocrine tumors.

Authors:  Emilija Manojlovic-Gacic; Britt Edén Engström; Olivera Casar-Borota
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

View more
  21 in total

1.  Endoscopic vs. microscopic transsphenoidal surgery outcomes in 514 nonfunctioning pituitary adenoma cases.

Authors:  Shuaihua Song; Linping Wang; Qianjin Qi; Haoran Wang; Li Feng
Journal:  Neurosurg Rev       Date:  2022-03-01       Impact factor: 3.042

2.  Estimating Risk of Pituitary Apoplexy after Resection of Giant Pituitary Adenomas.

Authors:  John T Butterfield; Takako Araki; Daniel Guillaume; Ramachandra Tummala; Emiro Caicedo-Granados; Matthew A Tyler; Andrew S Venteicher
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-22

3.  Transsphenoidal Surgery of Giant Pituitary Adenoma: Results and Experience of 239 Cases in A Single Center.

Authors:  Yike Chen; Xiaohui Xu; Jing Cao; Yuanqing Jie; Linkai Wang; Feng Cai; Sheng Chen; Wei Yan; Yuan Hong; Jianmin Zhang; Qun Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-06       Impact factor: 6.055

4.  Status and clinical and radiological predictive factors of presurgical anterior pituitary function in pituitary adenomas. Study of 232 patients.

Authors:  Marta Araujo-Castro; Eider Pascual-Corrales; Alberto Acitores Cancela; Sara García Duque; Luis Ley Urzaiz; Víctor Rodríguez Berrocal
Journal:  Endocrine       Date:  2020-08-12       Impact factor: 3.633

5.  LncRNA growth arrest specific transcript 5 inhibits the growth of pituitary neuroendocrine tumors via miR-27a-5p/cylindromatosis axis.

Authors:  Heyuan Wang; Bing Wu; Haotian Wang; Chunyan Jiang; Zhonghui Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

6.  Pituitary Adenoma Surgery Survey: Neurosurgical Centers and Pituitary Adenomas.

Authors:  David Netuka; Andre Grotenhuis; Nicolas Foroglou; Francesco Zenga; Sebastien Froehlich; Florian Ringel; Nicolas Sampron; Nick Thomas; Martin Komarc; Martin Majovsky
Journal:  Int J Endocrinol       Date:  2022-04-11       Impact factor: 2.803

7.  Practice patterns in the management of recurrent and residual non-functioning pituitary adenomas: Results from a Canada-wide survey.

Authors:  Graham Kasper; Nardin Samuel; Ryan Alkins; Osaama H Khan
Journal:  eNeurologicalSci       Date:  2021-01-22

8.  FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Authors:  Bin Zhu; Juan Wang; Lingling Qin; Lei Wang; Yanfei Zheng; Lei Zhang; Wei Wang
Journal:  Biosci Rep       Date:  2018-11-09       Impact factor: 3.840

9.  A Unilateral Nasal Mass With Generalized Seizures: Potential Diagnostic Pitfalls in Giant Pituitary Adenoma.

Authors:  Rahimah Aini; Ida Sadja'ah Sachlin; Lai Chuang Chee; Baharudin Abdullah
Journal:  Allergy Rhinol (Providence)       Date:  2019-12-17

10.  BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.

Authors:  Chengzhang Shi; Zhao Ye; Jie Han; Xiaoqing Ye; Wenchao Lu; Chenxing Ji; Zizhou Li; Zengyi Ma; Qilin Zhang; Yichao Zhang; Wenqiang He; Zhengyuan Chen; Xiaoyun Cao; Xuefei Shou; Xiang Zhou; Yongfei Wang; Zhaoyun Zhang; Yiming Li; Hongying Ye; Min He; Hong Chen; Haixia Cheng; Jun Sun; Jianyong Cai; Chuanxin Huang; Fei Ye; Cheng Luo; Bing Zhou; Hong Ding; Yao Zhao
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.